STOCK TITAN

PMV Pharmaceuticals (PMVP) Financials

PMVP NASDAQ
Trailing 12 months to September 30, 2026
Net Income -$88.5M n/m YoY
EPS (Diluted) -$1.54 n/m YoY
Free Cash Flow -$69.6M YoY not available
Operating Cash Flow -$69.6M n/m YoY
Market Cap $99.0M as of Nov 19, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.7x on $57.1M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PMVP SEC filings page.

This page shows PMV Pharmaceuticals, Inc (PMVP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PMVP FY2025

PMV remains a development-stage business: rising research spending and persistent cash losses are shrinking its financing base.

Assets contracted 39.1% from FY2024 to FY2025 even as the company consumed $73.6M in operating cash, indicating that the smaller balance sheet reflects funding depletion rather than operating efficiency. Equity also fell 40.5%, tying the contraction to accumulated losses rather than lower liabilities alone.

R&D spending rose 19.4% while SG&A fell 39.3% in FY2025, indicating a deliberate shift toward research rather than broad cost-cutting. That reallocation did not yet improve cash conversion: the company consumed $73.6M in operating cash against a net loss of $77.7M.

Liabilities were only 10.2% of assets in FY2025, while reported liquidity equaled 18.4 months of the latest annual operating outflow; this describes the reported balance-sheet position, not a forecast. Equity fell from $176.1M in FY2024 to $104.7M in FY2025, showing losses are consuming the financing base despite modest liabilities.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for PMV Pharmaceuticals, Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

PMV Pharmaceuticals, Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

PMV Pharmaceuticals, Inc reported a net loss of $77.7M while operations used $73.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$20.0M
YoYn/m
QoQn/m

PMV Pharmaceuticals, Inc's EBITDA was -$20.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$34.4M
YoYn/m
QoQn/m
5Y CAGRn/m

PMV Pharmaceuticals, Inc reported a net loss of $34.4M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.52
YoYn/m
QoQn/m
5Y CAGRn/m

PMV Pharmaceuticals, Inc earned -$0.52 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$18.2M
QoQn/m

PMV Pharmaceuticals, Inc recorded an outflow of $18.2M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$20.0M
YoY-45.0%
QoQ+60.3%
5Y CAGR-35.3%

PMV Pharmaceuticals, Inc held $20.0M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
76M
YoY+42.0%
QoQ+41.3%
5Y CAGR+10.7%

PMV Pharmaceuticals, Inc had 76M shares outstanding in Q3 2026. This represents an increase of 42.0% from the same quarter a year earlier. Against the prior quarter it is up 41.3%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-60.2%
YoY-42.8pp
QoQ-34.9pp
5Y change-55.6pp

PMV Pharmaceuticals, Inc's quarterly ROE was -60.2% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 42.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 34.9 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$16.1M
YoY-11.8%
QoQ+9.5%
5Y CAGR+11.9%

PMV Pharmaceuticals, Inc invested $16.1M in research and development in Q3 2026. This represents a decrease of 11.8% from the same quarter a year earlier. Against the prior quarter it is up 9.5%.

Capital Expenditures
$0
QoQn/m

PMV Pharmaceuticals, Inc reported no capital expenditure in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Share Buybacks

Not reported for Q3 2026.

PMVP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PMVP quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$16.1M-11.8%$14.7M-20.2%$15.3M-12.1%$15.8M+15.0%$18.2M+7.5%$18.4M+25.8%$17.4M+32.3%$13.8M+2.9%
SG&A Expenses$4.0M-7.2%$4.2M-6.1%$3.7M-10.5%$3.4M-70.1%$4.3M-12.7%$4.5M-19.2%$4.1M-18.1%$11.4M+106.6%
Operating Income-$20.1Mn/m-$18.9Mn/m-$19.0Mn/m-$19.2Mn/m-$22.5Mn/m-$22.9Mn/m-$21.6Mn/m-$25.2Mn/m
EBITDA-$20.0Mn/m-$18.9Mn/m-$19.0Mn/mN/A-$22.5Mn/m-$22.8Mn/m-$21.5Mn/mN/A
Income Tax-$7Kn/m$3K-40.0%N/A$26K-$6K-108.1%$5Kn/m-$2.2MN/A
Net Income-$34.4Mn/m-$18.1Mn/m-$18.0Mn/m-$18.0Mn/m-$21.1Mn/m-$21.2Mn/m-$17.4Mn/m-$23.0Mn/m
EPS (Basic)-$0.52n/m-$0.34n/m-$0.34n/m-$0.34n/m-$0.40n/m-$0.41n/m-$0.34n/m-$0.45n/m
EPS (Diluted)-$0.52n/m-$0.34n/m-$0.34n/m-$0.34n/m-$0.40n/m-$0.41n/m-$0.34n/m-$0.45n/m
Diluted Shares (Avg)66M+25.0%53M+2.6%53M+2.7%N/A53M+2.8%52M+1.0%52M+1.0%N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

PMVP Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PMVP quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$111.4M-16.8%$82.1M-46.3%$96.6M-43.4%$116.6M-39.1%$133.8M-40.1%$152.9M-35.7%$170.6M-28.0%$191.3M-24.1%
Current Assets$104.9M-20.8%$81.4M-44.0%$95.8M-41.4%$115.2M-34.4%$132.4M-30.2%$145.3M-33.6%$163.5M-19.2%$175.7M-15.3%
Cash & Equivalents$20.0M-45.0%$12.5M-71.7%$39.1M-23.8%$38.0M-7.1%$36.3M-25.6%$44.1M-9.1%$51.3M+7.7%$40.9M+8.4%
Short-Term Investments$82.6M-11.1%$67.0M-31.8%$54.4M-50.1%$75.0M-41.7%$92.9M-30.7%$98.1M-40.3%$109.0M-27.4%$128.6M-22.2%
Long-Term Investments$6.0Mn/m$0-100.0%$0-100.0%$0-100.0%$0-100.0%$6.0Mn/m$5.4M-64.1%$13.8M-45.7%
Total Liabilities$54.3M+322.7%$10.6M-13.7%$8.6M-18.2%$11.8M-22.1%$12.8M-49.8%$12.3M-47.3%$10.5M-56.6%$15.2M-42.5%
Current Liabilities$10.7M-13.1%$10.6M-9.0%$8.6M-11.9%$11.4M-20.6%$12.3M-9.3%$11.6M+1.9%$9.8M-19.1%$14.4M+2.4%
Non-Current Liabilities$43.6M+7960.4%$0-100.0%$0-100.0%$435K-48.1%$541K-95.5%$643K-94.6%$742K-93.9%$838K-93.3%
Total Equity$57.1M-52.8%$71.5M-49.1%$88.0M-45.1%$104.7M-40.5%$121.0M-38.9%$140.6M-34.4%$160.1M-24.7%$176.1M-22.0%
Retained Earnings-$517.0Mn/m-$482.6Mn/m-$464.5Mn/m-$446.5Mn/m-$428.4Mn/m-$407.4Mn/m-$386.1Mn/m-$368.7Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

PMVP Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PMVP quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$18.2Mn/m-$14.6Mn/m-$19.7Mn/m-$17.2Mn/m-$19.8Mn/m-$18.3Mn/m-$18.3Mn/m-$16.7Mn/m
Depreciation & Amortization$23K-28.1%$24K-25.0%$34K-8.1%$33K-15.4%$32K-91.4%$32K-91.4%$37K-89.8%$39K-89.1%
Stock-Based Compensation$1.6M+16.1%$1.5M-7.5%$1.4M-7.7%N/A$1.4M-37.8%$1.7M-39.7%$1.5M-42.2%N/A
Capital Expenditures$0$0-100.0%$0-100.0%$15K-73.2%N/A$11K+175.0%$4K-99.3%$56K-71.6%
Free Cash Flow-$18.2M-$14.6Mn/m-$19.7Mn/m-$17.2Mn/mN/A-$18.3Mn/m-$18.3Mn/m-$16.7Mn/m
Investing Cash Flow-$21.2M-276.2%-$12.2M-211.3%$20.8M-27.5%$18.4M+138.2%$12.0M-29.7%$11.0M+372.9%$28.7M+9.7%$7.7Mn/m
Financing Cash Flow$46.9Mn/m$143K+38.8%$0-100.0%$392K+127.9%$0n/m$103K-27.0%$10Kn/m$172K-40.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PMVP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PMVP quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-60.2%-42.8pp-25.3%-10.2pp-20.5%-9.6pp-17.2%-4.2pp-17.4%-7.7pp-15.1%-14.5pp-10.9%-3.7pp-13.1%-6.1pp
Return on Assets-30.9%-15.1pp-22.0%-8.2pp-18.7%-8.5pp-15.5%-3.5pp-15.7%-7.1pp-13.9%-13.4pp-10.2%-3.8pp-12.0%-5.8pp
Current Ratio9.81-1.0x7.70-4.8x11.14-5.6x10.09-2.1x10.76-3.2x12.52-6.7x16.750.0x12.22-2.6x
Liabilities-to-Equity0.95+0.8x0.15+0.1x0.100.0x0.110.0x0.110.0x0.090.0x0.070.0x0.090.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
PMV Pharmaceuticals, Inc PMVP FY2025 N/A -$77.7M N/A $99.0M —
Black Diamond Therapeutics, Inc. BDTX FY2025 $70.0M $22.4M 31.9% $79.9M 68/100
OnKure Therapeutics, Inc. OKUR FY2025 N/A -$59.5M N/A $113.7M —
Kazia Therapeutics Limited KZIA FY2025 $28K -$13.6M N/A $83.5M —
TuHURA Biosciences, Inc. HURA FY2025 $0 -$30.1M N/A $89.4M —
Anavex Life Sciences AVXL FY2025 N/A -$46.4M N/A $61.9M —

Frequently Asked Questions

No, PMV Pharmaceuticals, Inc (PMVP) reported a net loss of $88.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $77.7M.

PMV Pharmaceuticals, Inc (PMVP) reported diluted earnings per share of -$1.48 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PMV Pharmaceuticals, Inc (PMVP) had EBITDA of -$86.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

PMV Pharmaceuticals, Inc (PMVP) has a return on equity of -74.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

PMV Pharmaceuticals, Inc (PMVP) recorded an outflow of $73.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

PMV Pharmaceuticals, Inc (PMVP) recorded an outflow of $73.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

PMV Pharmaceuticals, Inc (PMVP) had $116.6M in total assets as of fiscal year 2025, including both current and long-term assets.

PMV Pharmaceuticals, Inc (PMVP) invested $29K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

PMV Pharmaceuticals, Inc (PMVP) invested $69.9M in research and development during fiscal year 2025.

PMV Pharmaceuticals, Inc (PMVP) had 53M shares outstanding as of fiscal year 2025.

PMV Pharmaceuticals, Inc (PMVP) had a current ratio of 10.09 as of fiscal year 2025, which is generally considered healthy.

PMV Pharmaceuticals, Inc (PMVP) had a liabilities-to-equity ratio of 0.11 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

PMV Pharmaceuticals, Inc (PMVP) had a return on assets of -66.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

PMV Pharmaceuticals, Inc (PMVP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $99.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

PMV Pharmaceuticals, Inc (PMVP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $99.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, PMV Pharmaceuticals, Inc (PMVP) held $112.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $73.6M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

PMV Pharmaceuticals, Inc (PMVP) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

PMV Pharmaceuticals, Inc (PMVP) reported a net loss of $77.7M while operations used $73.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top